Martina Hinterleitner

DFG Cluster Of Excellence 2180 'Image Guided And Functional Instructed Tumor Therapy'
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Primary Renal Neuroendocrine Tumor: Diagnostic Challenges in a Rare Entity-A Case Report.

Primary Renal Neuroendocrine Tumor: Diagnostic Challenges in a Rare Entity-A Case Report.

Journal: Current oncology (Toronto, Ont.)
Published: December 12, 2025

Cardiac Metastases in Neuroendocrine Neoplasms: A Single-Center Experience of Clinical Characteristics and Outcomes.

Cardiac Metastases in Neuroendocrine Neoplasms: A Single-Center Experience of Clinical Characteristics and Outcomes.

Journal: Cancers
Published: October 31, 2025

Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer.

Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 31, 2025

One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.

One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.

Journal: European journal of nuclear medicine and molecular imaging
Published: September 13, 2024

Low-activity [18F]-somatostatin receptor (SSTR) imaging using [18F]SiTATE on a long axial field-of-view PET/CT scanner.

Low-activity [18F]-somatostatin receptor (SSTR) imaging using [18F]SiTATE on a long axial field-of-view PET/CT scanner.

Journal: EJNMMI physics
Published: May 20, 2024

Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.

Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.

Journal: Clinical nuclear medicine
Published: January 25, 2024

Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.

Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.

Journal: Frontiers in endocrinology
Published: September 03, 2023

Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance-A Retrospective, Long-Term Single-Center Experience.

Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance-A Retrospective, Long-Term Single-Center Experience.

Journal: Cancers
Published: July 31, 2023

Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report.

Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report.

Journal: Experimental and therapeutic medicine
Published: February 21, 2023

Long-term prognostic factors for PRRT in neuroendocrine tumors.

Long-term prognostic factors for PRRT in neuroendocrine tumors.

Journal: Frontiers in medicine
Published: February 20, 2023

NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma.

NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma.

Journal: Journal of cancer research and clinical oncology
Published: January 05, 2023

Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients.

Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients.

Journal: Journal of clinical medicine
Published: August 25, 2022
Showing 1-12 of 27

Last Updated: 09/26/2026